These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 6271827)

  • 21. The effects of delta 9-tetrahydrocannabinol alone and in combination with cannabidiol on fixed-interval performance in rhesus monkeys.
    Brady KT; Balster RL
    Psychopharmacology (Berl); 1980; 72(1):21-6. PubMed ID: 6258188
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacological interaction of the effects of delta 9-trans-tetrahydrocannabinol and cannabidiol on serum corticosterone levels in rats.
    Zuardi AW; Teixeira NA; Karniol IC
    Arch Int Pharmacodyn Ther; 1984 May; 269(1):12-9. PubMed ID: 6087750
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characteristics of the stimulus produced by the mixture of cannabidiol with delta 9-tetrahydrocannabinol.
    Zuardi AW; Finkelfarb E; Bueno OF; Musty RE; Karniol IG
    Arch Int Pharmacodyn Ther; 1981 Jan; 249(1):137-46. PubMed ID: 6261703
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of delta 9-tetrahydrocannabinol, cannabinol and cannabidiol on the immune system in mice. I. In vivo investigation of the primary and secondary immune response.
    Baczynsky WO; Zimmerman AM
    Pharmacology; 1983; 26(1):1-11. PubMed ID: 6298841
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regulation of adenylate cyclase by cannabinoid drugs. Insights based on thermodynamic studies.
    Howlett AC; Scott DK; Wilken GH
    Biochem Pharmacol; 1989 Oct; 38(19):3297-304. PubMed ID: 2554920
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cannabidiol-Δ
    Britch SC; Wiley JL; Yu Z; Clowers BH; Craft RM
    Drug Alcohol Depend; 2017 Jun; 175():187-197. PubMed ID: 28445853
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tolerance to the cardiovascular effects of delta9-tetrahydrocannabinol in the rat.
    Adams MD; Chait LD; Earnhardt JT
    Br J Pharmacol; 1976 Jan; 56(1):43-8. PubMed ID: 1252665
    [TBL] [Abstract][Full Text] [Related]  

  • 28. delta 1-Tetrahydrocannabinol but not cannabidiol reduces contact and aggressive behavior of rats tested in dyadic encounters.
    van Ree JM; Niesink RJ; Nir I
    Psychopharmacology (Berl); 1984; 84(4):561-5. PubMed ID: 6098915
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiovascular system effects of marijuana.
    Jones RT
    J Clin Pharmacol; 2002 Nov; 42(S1):58S-63S. PubMed ID: 12412837
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effects of delta 9-tetrahydrocannabinol, cannabidiol, and shock on plasma corticosterone concentrations in rats.
    Jacobs JA; Dellarco AJ; Manfredi RA; Harclerode J
    J Pharm Pharmacol; 1979 May; 31(5):341-2. PubMed ID: 37310
    [No Abstract]   [Full Text] [Related]  

  • 31. Pharmacokinetics and pharmacodynamics of cannabinoids.
    Grotenhermen F
    Clin Pharmacokinet; 2003; 42(4):327-60. PubMed ID: 12648025
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiovascular effects of (-)-11-OH-delta 8-tetrahydrocannabinol-dimethylheptyl in rats.
    Vidrio H; Sánchez-Salvatori MA; Medina M
    J Cardiovasc Pharmacol; 1996 Aug; 28(2):332-6. PubMed ID: 8856492
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of prolonged administration of delta 9-tetrahydrocannabinol on the autonomic and cardiovascular function and regional hemodynamics in mongrel dogs.
    Jandhyala BS
    Res Commun Chem Pathol Pharmacol; 1978 Jun; 20(3):489-508. PubMed ID: 674828
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changes in neurotransmitter release at a neuromuscular junction of the lobster caused by cannabinoids.
    Turkanis SA; Karler R
    Neuropharmacology; 1988 Jul; 27(7):737-42. PubMed ID: 2901683
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacology of cannabinoids in the treatment of epilepsy.
    Gaston TE; Friedman D
    Epilepsy Behav; 2017 May; 70(Pt B):313-318. PubMed ID: 28087250
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ocular hypotension, ocular toxicity, and neurotoxicity in response to marihuana extract and cannabidiol.
    Colasanti BK; Brown RE; Craig CR
    Gen Pharmacol; 1984; 15(6):479-84. PubMed ID: 6098513
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of 22-day treatment on the anticonvulsant properties of cannabinoids.
    Karler R; Borys HK; Turkanis SA
    Naunyn Schmiedebergs Arch Pharmacol; 1982 Aug; 320(2):105-9. PubMed ID: 6289137
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of delta-9-tetrahydrocannabinol, cannabinol and cannabidiol, alone and in combinations, on luteinizing hormone and prolactin release and on hypothalamic neurotransmitters in the male rat.
    Murphy LL; Steger RW; Smith MS; Bartke A
    Neuroendocrinology; 1990 Oct; 52(4):316-21. PubMed ID: 1979838
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interactions in man of delta-9-tetrahydrocannabinol. II. Cannabinol and cannabidiol.
    Hollister LE; Gillespie H
    Clin Pharmacol Ther; 1975 Jul; 18(1):80-3. PubMed ID: 1097148
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ¹H NMR and HPLC/DAD for Cannabis sativa L. chemotype distinction, extract profiling and specification.
    Peschel W; Politi M
    Talanta; 2015 Aug; 140():150-165. PubMed ID: 26048837
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.